Table 3– Treatment outcomes by multidrug-resistant tuberculosis (MDR-TB) patient group
Pooled treatment outcomes#MDR-TB onlyMDR-TB +INJrMDR-TB +FQrXDR-TBTotal
Treatment success64 (57–72)56 (45–66)48 (36–60)40 (27–53)62 (54–69)
Treatment failure or relapse4 (2–6)12 (9–15)18 (14–21)22 (15–28)7 (4–9)
Died8 (5–11)8 (3–14)11 (3–19)15 (8–23)9 (5–12)
Defaulted18 (12–24)16 (7–24)12 (1–23)16 (8–24)17 (11–22)
  • Data are presented as n or % (95% CI). MDR-TB: multidrug-resistant TB (resistance to at least isoniazid and rifampicin); MDR-TB only: as MDR-TB, but susceptible to fluoroquinolones, amikacin/kanamycin and capreomycin (at least one second-line injectable drug tested); MDR-TB+INJr: MDR-TB plus resistance to amikacin/kanamycin and/or capreomycin, but susceptible to fluoroquinolones; MDR-TB+FQr: MDR-TB plus resistance to any fluoroquinolone, but susceptible to amikacin/kanamycin and/or capreomycin (at least one second-line injectable drug tested); XDR-TB: extensively drug-resistant tuberculosis (MDR-TB plus resistance to any fluoroquinolone and any second-line injectable drug (amikacin/kanamycin and/or capreomycin)). #: from study level meta-analysis; column percentages do not total 100%. See the Methods section and [17] for treatment outcome definitions.